Estonia vs Saudi Arabia: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Estonia
- Saudi Arabia
How they compare
Saudi Arabia currently reports 247.11 deaths against 217.74 deaths in Estonia, a difference of 29.37 deaths.
That makes Saudi Arabia's figure about 1.1 times Estonia's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Saudi Arabia ahead.
Estonia ranks 108th and Saudi Arabia ranks 107th of 157 countries.
Across the 4 decades both report, Estonia averaged higher in 2 and Saudi Arabia in 2.
Head to head by decade
| Decade | Estonia | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 56.24 deaths | 56.24 deaths | Saudi Arabia |
| 2000s | 76.25 deaths | 210.83 deaths | 134.58 deaths | Saudi Arabia |
| 2010s | 296.88 deaths | 142.31 deaths | 154.57 deaths | Estonia |
| 2020s | 240.39 deaths | 221.23 deaths | 19.16 deaths | Estonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Estonia or Saudi Arabia?
- Saudi Arabia, at 247.11 deaths against 217.74 deaths in Estonia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Estonia and Saudi Arabia?
- 29.37 deaths, with Saudi Arabia ahead.
- How many years of comparable data are there for Estonia and Saudi Arabia?
- 35 years are reported by both, from 1990 to 2024.
- How do Estonia and Saudi Arabia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Estonia ranks 108th and Saudi Arabia ranks 107th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.